RHA® Redensity With New Anesthetic Agent Perioral Rhytids (PAS)

NAActive, not recruitingINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

June 11, 2024

Primary Completion Date

February 26, 2025

Study Completion Date

September 30, 2025

Conditions
PainAging
Interventions
DEVICE

RHA® Redensity with new anesthetic agent

A sterile, biodegradable, biocompatible, viscoelastic, clear, colorless, homogenized gel implant. It consists of cross-linked hyaluronic acid produced by fermentation of Streptococcus zooepidemicus, formulated to a concentration of 15 mg/g and 0.3% w/w of new anesthetic agent in a physiologic buffer.

DEVICE

RHA® Redensity with lidocaine

A sterile, biodegradable, biocompatible, viscoelastic, clear, colorless, homogenized gel implant. It consists of cross-linked hyaluronic acid produced by fermentation of Streptococcus zooepidemicus, formulated to a concentration of 15 mg/g and 0.3% w/w lidocaine in a physiologic buffer.

Trial Locations (3)

10028

United States, New York, New York

35209

United States, Birmingham

00917

Puerto Rico, San Juan

All Listed Sponsors
lead

Teoxane SA

INDUSTRY

NCT06378086 - RHA® Redensity With New Anesthetic Agent Perioral Rhytids (PAS) | Biotech Hunter | Biotech Hunter